How effective is stem cell therapy?
Stem cell therapy is effective for many patients, and how effective it is depends on the condition being treated.
The strongest evidence is in musculoskeletal problems: in knee osteoarthritis, a 2024 meta-analysis of randomized controlled trials found that mesenchymal stem cell (MSC) injections reduced pain more than hyaluronic acid at 12 months and improved function, and in degenerative disc disease, a 2026 meta-analysis of randomized trials found greater pain reduction with intradiscal MSCs than with control treatments. Evidence is growing for neurological, cardiovascular, kidney and healthy aging goals, with randomized trials reporting improvements such as better motor function in children with cerebral palsy, better heart function in heart failure and better walking distance in older adults with frailty. Across conditions, large safety analyses show a favorable safety profile. At Stem Cell Mexico, treatment uses only allogeneic MSCs from Wharton's jelly of the umbilical cord. Results vary from patient to patient, and they are best measured against clear goals.
This guide summarizes effectiveness by area, explains the factors that make the biggest difference and shows how to measure your own results.
How stem cell therapy produces results
MSCs from Wharton's jelly work through paracrine signaling: they release anti-inflammatory, immune-modulating and trophic factors that calm inflammation, protect cells, support the formation of small blood vessels and activate the body's own repair processes. They do not turn into large amounts of new tissue. This explains both what treatment can achieve, less pain, better function and support for tissue health, and why results develop gradually over weeks to months.
Effectiveness by area
Strongest evidence: joints and spine
- Knee osteoarthritis: the 2024 meta-analysis in the Journal of Orthopaedic Translation found greater pain reduction than hyaluronic acid at 12 months and improved function, with no difference in serious adverse events compared with control treatments. A randomized trial of umbilical cord MSCs in Stem Cells Translational Medicine found significantly better pain and function scores at 12 months than hyaluronic acid.
- Degenerative disc disease: the 2026 meta-analysis in the Asian Spine Journal included seven randomized trials with 594 patients and found greater pain reduction with intradiscal MSCs, with benefits that became more evident over time.
What it means: many patients with mild to moderate osteoarthritis or disc-related pain experience meaningful pain relief and better function, and some postpone surgery.
Growing evidence: neurological conditions
- Cerebral palsy: a randomized, double-blind, placebo-controlled trial of IV umbilical cord MSCs found greater improvement in gross motor function and daily activities than placebo.
- Stroke: a Cochrane review of randomized trials found that stem cell transplantation was associated with reduced neurological impairment.
- Spinal cord injury, multiple sclerosis and Parkinson's disease: clinical studies show a favorable safety profile and improvements in some patients.
What it means: gains in specific functions, such as motor control, balance or energy, especially combined with rehabilitation.
Growing evidence: heart, kidney and metabolic conditions
- Heart failure: a randomized trial of IV umbilical cord MSCs reported improvements in ejection fraction and quality of life.
- Chronic kidney disease: a 2025 meta-analysis found reductions in protein leakage in the urine.
What it means: support for function and quality of life, measured with objective tests, alongside standard medical care.
Growing evidence: healthy aging and specific goals
- Frailty and aging: a randomized, placebo-controlled trial found better walking distance and lower inflammatory markers after MSC infusions.
- Erectile dysfunction and hair: human studies report improvements in erectile function scores and in hair density with stem cell and exosome treatments.
Safety across conditions
A 2026 meta-analysis of IV umbilical-cord-derived MSCs in Stem Cells Translational Medicine found temporary fever as the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled trials. Local injections commonly cause temporary pain, swelling or stiffness for a few days. No treatment is free of risk, which is why screening and monitoring are part of every protocol.
What makes the biggest difference in effectiveness
- The right diagnosis: treating the true source of the problem.
- The stage: earlier stages offer more opportunity.
- The right protocol: route, image guidance and number of cells matched to the target.
- Rehabilitation: exercise and therapy turn reduced pain or inflammation into function.
- General health: controlled blood sugar, blood pressure and weight; no smoking.
- Clear goals and measurement: knowing what you want to change and tracking it.
How to measure effectiveness for yourself
| Goal | Simple measure |
|---|---|
| Joint pain | Pain score (0 to 10), walking distance, stairs |
| Back pain | Pain score, sitting tolerance, disability questionnaire |
| Neurological | Standardized scales with your therapists, videos |
| Heart or kidney | Echocardiogram, BNP, eGFR, urine protein |
| Energy | Daily rating, six-minute walk |
| Hair | Standardized photographs |
Recording these before treatment and at one, three and six months shows clearly what changed.
A typical timeline
- Joint and spine pain: based on what patients tell us, many notice less pain within days to weeks, with improvement continuing over three to six months.
- Neurological and systemic goals: changes usually develop over two to six months.
- Hair and skin: three to six months.
What patients commonly report
When treatment works well, patients describe practical gains: walking or climbing stairs with less pain, sleeping better, returning to exercise or a hobby, more energy during the day and, in neurological conditions, small but meaningful improvements in movement or independence. Some improve a great deal, others more modestly, which is why measuring before and after matters.
How stem cell therapy compares with other options
For many conditions, regenerative treatment sits between conservative care and surgery:
- Compared with painkillers and anti-inflammatory drugs, it aims to change the tissue environment rather than only mask pain, and it avoids the long-term side effects of daily medication.
- Compared with cortisone injections, which often bring fast but short relief, regenerative treatment works more gradually and, in knee osteoarthritis trials, has been followed for one to two years.
- Compared with surgery, it is minimally invasive, requires no hospital stay of several days and allows a quick return to light activities, although advanced damage may still need surgery.
- Compared with rehabilitation alone, it can make exercise easier by reducing pain and inflammation, and the two work best together.
Questions patients often ask
Is it more effective in younger patients? Age matters less than the stage of the condition and general health. Older adults with mild to moderate problems can respond well.
Is it effective if other treatments failed? Many patients come to us after medications, injections or therapy did not give enough relief. The evaluation reviews why previous treatments did not work and whether regenerative treatment is likely to add benefit.
Does a higher number of cells mean more effectiveness? Not necessarily. The number of cells is chosen for the target and route, and more is not always better, especially in confined spaces such as a joint.
Can effectiveness improve with a second application? In some cases, yes. The decision is based on how you responded the first time.
What our patients usually receive
Based on the treatment plans our team prepares, typical protocols at Stem Cell Mexico include:
- For joints or the spine: 20 to 40 million Wharton's jelly MSCs per area by direct injection with image guidance, often with platelet-rich plasma (PRP).
- For systemic and neurological goals: IV infusion, usually 100 to 200 million cells, and in selected neurological cases an additional intrathecal application.
- One night at our facilities, the consultation with your doctor and the stem cell specialist, and ground transportation from the San Diego airport area.
Treatment plans range from about $1,800 to $9,500 USD, depending on the condition. Our team stays in contact after treatment to follow your progress and decide whether a second application could help.
How to know if treatment is right for you
The International Society for Stem Cell Research (ISSCR) encourages patients to understand the evidence for their condition, how the cells are prepared and how safety is monitored. Our medical evaluation answers these questions for your case and tells you honestly when treatment is unlikely to help.
Questions to ask during your evaluation
- How effective is treatment likely to be for my condition and stage?
- Which route and how many cells are recommended?
- How will we measure results, and when?
- What can I do to improve my result?
Bottom line
Stem cell therapy is effective for many patients, with the strongest evidence in knee osteoarthritis and degenerative disc disease, growing evidence for neurological, cardiovascular, kidney and healthy aging goals, and a favorable safety profile across conditions. At Stem Cell Mexico, Wharton's jelly MSCs are applied according to your goal, and results vary from patient to patient. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your condition, goals and medical history.
References
- Tabet CG et al. Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Translation, 2024 (opens in a new tab)
- Matas J et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Translational Medicine, 2019 (opens in a new tab)
- Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
- Gu J et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy, 2020 (opens in a new tab)
- Cochrane: Boncoraglio GB et al. Stem cell transplantation for ischemic stroke, 2019 (opens in a new tab)
- Bartolucci J et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial). Circulation Research, 2017 (opens in a new tab)
- Tompkins BA et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial. The Journals of Gerontology, Series A, 2017 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
